Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy

A Anton, Z Ballok, P Bowden, T Costello, L Harewood, N Corcoran, P Dundee, J Peters, N Lawrentschuk, A Troy, D Webb, Y Chan, A See, S Siva, D Murphy, MS Hofman, B Tran